 Home > Biochemistry News > Biotechnology News > oHCM innovative medicine!

oHCM innovative medicine!

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

oil chemical structure

morphine chemical structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bristol-Myers Squibb (BMS) recently announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for mavacamten, a new, oral, myosin allosteric modulator for the treatment of obstruction Hypertrophic cardiomyopathy (oHCM), which is a chronic heart disease with a high incidence

Currently, mavacamten's New Drug Application (NDA) for the treatment of symptomatic oHCM is also under review by the US FDA, and the target date of the Prescription Drug User Fee Act (PDUFA) is January 28, 2022

mavacamten is a first-in-class, oral, allosteric myosin inhibitor for the treatment of diseases that are inherently caused by excessive heart contraction and impaired diastolic filling

mavacamten was originally developed to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

The chemical structure of mavacamten (picture source: chemsrc.

Both mavacamten NDA and MAA are based on the results of the key Phase 3 EXPLORER-HCM trial

mavacamten (MYK-461) was developed by MyoKardia

It is worth noting that on August 11, 2020, LianBio, which was incubated by the investment company Perceptive Advisors, was formally established.

Note: The original text has been deleted

Original Source: European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.